Compare Pfizer Inc (PFE) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs S&P Global Inc — how do they compare? Pfizer Inc trades at $27.81 (market cap $159.59B), while S&P Global Inc trades at $403.38 (market cap $116.50B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and S&P Global Inc for 123 Days on average.
| PFE | SPGI | |
|---|---|---|
Market Cap | $159.59B | $116.50B |
Volume | 30,937,010 | 1,430,714 |
Sector | Health | Financials |
52-Week High | $29.02 | $517.92 |
52-Week Low | $23.67 | $370.42 |
Typical Hold Time | 158 Days | 123 Days |
Enterprise Value | $211.09B | $127.99B |
Dividend Yield | 6.14% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
S&P Global (SPGI) trades at $402.73, up 1.67% with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock faces technical headwinds with bearish moving averages but maintains robust fundamentals including 30.5% net margins and consistent revenue growth from $15.3B to $16.1B projected for 2026. Recent developments include expansion into digital asset risk assessment and the acquisition of OpenZeppelin, positioning the company for AI-driven growth across its financial services divisions.
The outlook remains positive given S&P Global's dominant market position and margin expansion potential, though investors should monitor debt levels increasing to 23.3% of assets. Near-term catalysts include Q3 2026 earnings on October 27, with the stock offering 26% upside to analyst targets despite current technical weakness suggesting potential entry points near $391 support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
